PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: IMARC Group

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Indian Therapeutic Monoclonal Antibodies Market to Grow at a CAGR of 27% During 2011-2016 Finds IMARC Group - The study, that has been undertaken using desk-based as well as qualitative primary market research provides and draws upon a comprehensive analysis of the Indian therapeutic monoclonal antibodies market - IMARCgroup.com
Indian Therapeutic Monoclonal Antibodies Market to Grow at a CAGR of 27% During 2011-2016 Finds IMARC Group

 

NewswireToday - /newswire/ - Noida, Uttar Pradesh, India, 2012/03/15 - The study, that has been undertaken using desk-based as well as qualitative primary market research provides and draws upon a comprehensive analysis of the Indian therapeutic monoclonal antibodies market - IMARCgroup.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

IMARC Group, one of the world’s leading research and advisory firms, in its latest study “Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016” finds that driven by factors such as a large patient pool, strong biomanufacturing capabilities, absence of an Indian patent for most in-market monoclonal antibodies and an increasing prevalence of health Insurance; the market for therapeutic monoclonal antibodies in India is expected to grow at a CAGR of 27% during 2011-2016. The study, that has been undertaken using desk-based as well as qualitative primary market research provides and draws upon a comprehensive analysis of the Indian therapeutic monoclonal antibodies market.

What we have achieved in this Report
Understanding the strengths, weaknesses, opportunities and challenges in the Indian therapeutic monoclonal antibodies market
Understanding the technological considerations and regulatory factors in the Indian therapeutic monoclonal antibodies market

• Evaluation and identification of monoclonal antibodies based on the sources from which they are derived and on the targets against which they act
• Understanding the key regulations for registering, manufacturing and importing therapeutic monoclonal antibodies in India
Evaluating the patent details of all globally marketed monoclonal antibodies in India, US and Europe
• Identifying the patentee name and patent numbers of all in-market monoclonal antibodies in India, US and Europe
• Identifying the monoclonal antibodies that are patent protected in India, US and Europe and those that are not
• Estimating the patent expiries of various monoclonal antibodies in India, US and Europe
Comprehensive situation analysis of the Indian therapeutic antibodies market
• Analyzing current and future sales of monoclonal antibodies in India
• Identifying all globally launched monoclonal antibodies and understanding their performance and launch status in India
• Analyzing the global and Indian monoclonal antibodies market by Indication
• Evaluation of the top selling monoclonal antibodies
• Key biosimilar antibody development programmes in India and abroad

Key Questions Answered in this Report

• What is the current size and growth of the Indian therapeutic monoclonal antibodies market?
• What are the most popular indications for which therapeutic monoclonal antibodies are prescribed in India?
• Who are the key players operating in the Indian therapeutic monoclonal antibodies market?
• Which are the top selling therapeutic monoclonal antibodies in India?
• What are the strengths, weaknesses, opportunities and threats in the Indian therapeutic monoclonal antibodies market?
• What are the key requirements to launch a therapeutic monoclonal antibody in India?
• What is the patent position of various in-market therapeutic monoclonal antibodies in India?
• Which therapeutic monoclonal antibodies are protected by a patent in India and when will their patents expire?
• Which therapeutic monoclonal antibodies already have biosimilars available in India?
• What are the key biosimilar monoclonal antibody development programmes in India?

To obtain the complete report, please contact

IMARC Group Asia
E: apac[.]imarcgroup.com

IMARC Group North America
E: america[.]imarcgroup.com - P: +1-631-791-1145.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: IMARC Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Indian Therapeutic Monoclonal Antibodies Market to Grow at a CAGR of 27% During 2011-2016 Finds IMARC Group

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Krishna Sharma - IMARCgroup.com 
+91 12 04155099 press[.]imarcgroup.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IMARC Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From IMARC Group / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)